Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

The evolution of poxvirus vaccines.

Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, García-Arriaza J, Di Pilato M, Esteban M.

Viruses. 2015 Apr 7;7(4):1726-803. doi: 10.3390/v7041726. Review.

2.

Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.

Richert L, Doussau A, Lelièvre JD, Arnold V, Rieux V, Bouakane A, Lévy Y, Chêne G, Thiébaut R; Vaccine Research Institute (VRI).

Trials. 2014 Feb 26;15:68. doi: 10.1186/1745-6215-15-68.

3.

Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.

García-Arriaza J, Gómez CE, Sorzano CÓ, Esteban M.

J Virol. 2014 Mar;88(6):3392-410. doi: 10.1128/JVI.02723-13. Epub 2014 Jan 3.

4.

Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa.

Schmidt C, Jaoko W, Omosa-Manyonyi G, Kaleebu P, Mpendo J, Nanvubya A, Karita E, Bayingana R, Bekker LG, Chomba E, Kilembe W, Nchabeleng M, Nyombayire J, Stevens G, Chetty P, Lehrman J, Cox J, Allen S, Dally L, Smith C, Fast PE.

Hum Vaccin Immunother. 2014;10(3):714-23. Epub 2013 Dec 27.

5.

Delivery strategies for novel vaccine formulations.

Trovato M, Krebs SJ, Haigwood NL, De Berardinis P.

World J Virol. 2012 Feb 12;1(1):4-10. doi: 10.5501/wjv.v1.i1.4.

6.

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.

García-Arriaza J, Arnáez P, Gómez CE, Sorzano CÓ, Esteban M.

PLoS One. 2013 Jun 27;8(6):e66894. doi: 10.1371/journal.pone.0066894. Print 2013.

7.

Novel directions in HIV-1 vaccines revealed from clinical trials.

Excler JL, Tomaras GD, Russell ND.

Curr Opin HIV AIDS. 2013 Sep;8(5):421-31. doi: 10.1097/COH.0b013e3283632c26. Review.

8.

Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review.

Elizaga ML, Vasan S, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, Frey SE, Keefer MC; MVA Cardiac Safety Working Group.

PLoS One. 2013;8(1):e54407. doi: 10.1371/journal.pone.0054407. Epub 2013 Jan 17.

9.

Human immunodeficiency virus vaccine trials.

O'Connell RJ, Kim JH, Corey L, Michael NL.

Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a007351. doi: 10.1101/cshperspect.a007351. Review.

10.

Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.

Perdiguero B, Gómez CE, Nájera JL, Sorzano CO, Delaloye J, González-Sanz R, Jiménez V, Roger T, Calandra T, Pantaleo G, Esteban M.

PLoS One. 2012;7(10):e48524. doi: 10.1371/journal.pone.0048524. Epub 2012 Oct 31.

11.

Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.

Garber DA, O'Mara LA, Gangadhara S, McQuoid M, Zhang X, Zheng R, Gill K, Verma M, Yu T, Johnson B, Li B, Derdeyn CA, Ibegbu C, Altman JD, Hunter E, Feinberg MB.

J Virol. 2012 Dec;86(23):12605-15. doi: 10.1128/JVI.00246-12. Epub 2012 Sep 12.

12.

Poxvirus vectors as HIV/AIDS vaccines in humans.

Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M.

Hum Vaccin Immunother. 2012 Sep;8(9):1192-207. doi: 10.4161/hv.20778. Epub 2012 Aug 21. Review.

13.

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.

Gómez CE, Perdiguero B, Jiménez V, Filali-Mouhim A, Ghneim K, Haddad EK, Quakkelaar ED, Delaloye J, Harari A, Roger T, Duhen T, Sékaly RP, Melief CJ, Calandra T, Sallusto F, Lanzavecchia A, Wagner R, Pantaleo G, Esteban M.

PLoS One. 2012;7(4):e35485. doi: 10.1371/journal.pone.0035485. Epub 2012 Apr 19. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/44b8f849-7885-4ad0-8fc9-b252c9ee1790. Dunhen, Thomas [corrected to Duhen, Thomas]. PLoS One. 2012;7(5): doi/10.1371/annotation/09c18b10-8433-4d64-be1c-61e578cc088b. Quakkerlaar [corrected to Quakkelaar, Esther D]..

14.

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Cox JH, Ferrari MG, Earl P, Lane JR, Jagodzinski LL, Polonis VR, Kuta EG, Boyer JD, Ratto-Kim S, Eller LA, Pham DT, Hart L, Montefiori D, Ferrari G, Parrish S, Weiner DB, Moss B, Kim JH, Birx D, VanCott TC.

Vaccine. 2012 Feb 27;30(10):1830-40. doi: 10.1016/j.vaccine.2011.12.131. Epub 2012 Jan 9.

15.

Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials.

Zembe L, Burgers WA, Jaspan HB, Bekker LG, Bredell H, Stevens G, Gilmour J, Cox JH, Fast P, Hayes P, Vardas E, Williamson C, Gray CM.

PLoS One. 2011;6(10):e26096. doi: 10.1371/journal.pone.0026096. Epub 2011 Oct 12.

16.

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.

García-Arriaza J, Nájera JL, Gómez CE, Tewabe N, Sorzano CO, Calandra T, Roger T, Esteban M.

PLoS One. 2011;6(8):e24244. doi: 10.1371/journal.pone.0024244. Epub 2011 Aug 31.

17.

The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.

Gómez CE, Nájera JL, Perdiguero B, García-Arriaza J, Sorzano CO, Jiménez V, González-Sanz R, Jiménez JL, Muñoz-Fernández MA, López Bernaldo de Quirós JC, Guardo AC, García F, Gatell JM, Plana M, Esteban M.

J Virol. 2011 Nov;85(21):11468-78. doi: 10.1128/JVI.05165-11. Epub 2011 Aug 24.

18.

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Godoy-Ramirez K, Joachim A, Polonis VR, Bråve A, Earl P, Robb M, Marovich M, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandström E.

Vaccine. 2011 Oct 26;29(46):8417-28. doi: 10.1016/j.vaccine.2011.08.001. Epub 2011 Aug 22.

19.

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L; NIAID HIV Vaccine Trials Network.

Vaccine. 2011 Feb 24;29(10):1948-58. doi: 10.1016/j.vaccine.2010.12.104. Epub 2011 Jan 7.

20.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.

PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.

Supplemental Content

Support Center